Motexafin lutetium

Motexafin lutetium
	source ↗
Names
	Other names Antrin; Lu texaphyrin; Lu-Tex; Lutetium texaphyrin; Lutrin; Optrin; PCI 0123
Identifiers
CAS Number	246252-04-0 Y;
3D model (JSmol)	Interactive image;
ChemSpider	31046954;
DrugBank	DB05296;
PubChem CID	3081907;
UNII	0V38NF6N89 Y;
	InChI InChI=1S/C48H66N5O10.2C2H4O2.Lu.H2O/c1-7-35-36(8-2)40-28-42-38(12-10-14-55)34(4)46(53-42)32-50-44-30-48(63-26-24-61-22-20-59-18-16-57-6)47(62-25-23-60-21-19-58-17-15-56-5)29-43(44)49-31-45-33(3)37(11-9-13-54)41(52-45)27-39(35)51-40;21-2(3)4;;/h27-32,54-55H,7-26H2,1-6H3;21H3,(H,3,4);;1H2/q-1;;;+3;/p-2 Key: WIQKYZYFTAEWBF-UHFFFAOYSA-L;
	SMILES CC([O-])=O.CCC1=C2[N-]C(/C=C3N=C(/C=N/C4=CC(OCCOCCOCCOC)=C(OCCOCCOCCOC)C=C4/N=C/C(C(C)=C/5CCCO)=[N]([Lu+3])C5=C/2)C(C)=C\3CCCO)=C1CC;
Properties
Chemical formula	C52H72LuN5O14
Molar mass	1166.136 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Y verify (what is YN ?) Infobox references

Motexafin lutetium is a texaphyrin, marketed as Antrin by Pharmacyclics Inc.

It is a photosensitiser for use in photodynamic therapy to treat skin conditions and superficial cancers.

It has also been tested for use in photoangioplasty (photodynamic treatment of diseased arteries).¹

It is photoactivated by 732 nm light which allows greater depth of penetration.²

Clinical trials

Phase II clinical trials were in progress in 1999.³

A phase I trial for prostate cancer reported in 2009.⁴

References